Global Optic Neuropathy Treatment Market Research Report 2023

Publication ID:

PB504230409

Publication Date:

April 20, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Optic neuropathy is a condition that affects the optic nerve, which is responsible for transmitting visual information from the eyes to the brain. This condition can result in vision loss, blurred vision, and other symptoms.
The global Optic Neuropathy Treatment market was valued at US$ 4095.3 million in 2022 and is anticipated to reach US$ 5762.4 million by 2029, witnessing a CAGR of 5.0% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Optic Neuropathy Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Optic Neuropathy Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Optic Neuropathy Treatment include AbbVie Inc., Eli Lilly and Company, GSK Plc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Bayer AG and Sanofi S.A, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Optic Neuropathy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Optic Neuropathy Treatment.
The Optic Neuropathy Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Optic Neuropathy Treatment market comprehensively. Regional market sizes, concerning products by route, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Optic Neuropathy Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by route, by application and by regions.
By Company
AbbVie Inc.
Eli Lilly and Company
GSK Plc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Bausch Health Companies Inc.
F. Hoffmann-La Roche AG
Bayer AG
Sanofi S.A
Bristol-Myers Squibb Company
Segment by Route
Oral
Injectable
Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Optic Neuropathy Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Optic Neuropathy Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by route, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Optic Neuropathy Treatment Market Overview
1.1 Product Overview and Scope of Optic Neuropathy Treatment
1.2 Optic Neuropathy Treatment Segment by Route
1.2.1 Global Optic Neuropathy Treatment Market Value Comparison by Route (2023-2029)
1.2.2 Oral
1.2.3 Injectable
1.3 Optic Neuropathy Treatment Segment by Application
1.3.1 Global Optic Neuropathy Treatment Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Online Pharmacies
1.3.4 Retail Pharmacies
1.4 Global Optic Neuropathy Treatment Market Size Estimates and Forecasts
1.4.1 Global Optic Neuropathy Treatment Revenue 2018-2029
1.4.2 Global Optic Neuropathy Treatment Sales 2018-2029
1.4.3 Global Optic Neuropathy Treatment Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Optic Neuropathy Treatment Market Competition by Manufacturers
2.1 Global Optic Neuropathy Treatment Sales Market Share by Manufacturers (2018-2023)
2.2 Global Optic Neuropathy Treatment Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Optic Neuropathy Treatment Average Price by Manufacturers (2018-2023)
2.4 Global Optic Neuropathy Treatment Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Optic Neuropathy Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Optic Neuropathy Treatment, Product Type & Application
2.7 Optic Neuropathy Treatment Market Competitive Situation and Trends
2.7.1 Optic Neuropathy Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Optic Neuropathy Treatment Players Market Share by Revenue
2.7.3 Global Optic Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Optic Neuropathy Treatment Retrospective Market Scenario by Region
3.1 Global Optic Neuropathy Treatment Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Optic Neuropathy Treatment Global Optic Neuropathy Treatment Sales by Region: 2018-2029
3.2.1 Global Optic Neuropathy Treatment Sales by Region: 2018-2023
3.2.2 Global Optic Neuropathy Treatment Sales by Region: 2024-2029
3.3 Global Optic Neuropathy Treatment Global Optic Neuropathy Treatment Revenue by Region: 2018-2029
3.3.1 Global Optic Neuropathy Treatment Revenue by Region: 2018-2023
3.3.2 Global Optic Neuropathy Treatment Revenue by Region: 2024-2029
3.4 North America Optic Neuropathy Treatment Market Facts & Figures by Country
3.4.1 North America Optic Neuropathy Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Optic Neuropathy Treatment Sales by Country (2018-2029)
3.4.3 North America Optic Neuropathy Treatment Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Optic Neuropathy Treatment Market Facts & Figures by Country
3.5.1 Europe Optic Neuropathy Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Optic Neuropathy Treatment Sales by Country (2018-2029)
3.5.3 Europe Optic Neuropathy Treatment Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Optic Neuropathy Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific Optic Neuropathy Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Optic Neuropathy Treatment Sales by Country (2018-2029)
3.6.3 Asia Pacific Optic Neuropathy Treatment Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Optic Neuropathy Treatment Market Facts & Figures by Country
3.7.1 Latin America Optic Neuropathy Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Optic Neuropathy Treatment Sales by Country (2018-2029)
3.7.3 Latin America Optic Neuropathy Treatment Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Optic Neuropathy Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Optic Neuropathy Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Optic Neuropathy Treatment Sales by Country (2018-2029)
3.8.3 Middle East and Africa Optic Neuropathy Treatment Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Route
4.1 Global Optic Neuropathy Treatment Sales by Route (2018-2029)
4.1.1 Global Optic Neuropathy Treatment Sales by Route (2018-2023)
4.1.2 Global Optic Neuropathy Treatment Sales by Route (2024-2029)
4.1.3 Global Optic Neuropathy Treatment Sales Market Share by Route (2018-2029)
4.2 Global Optic Neuropathy Treatment Revenue by Route (2018-2029)
4.2.1 Global Optic Neuropathy Treatment Revenue by Route (2018-2023)
4.2.2 Global Optic Neuropathy Treatment Revenue by Route (2024-2029)
4.2.3 Global Optic Neuropathy Treatment Revenue Market Share by Route (2018-2029)
4.3 Global Optic Neuropathy Treatment Price by Route (2018-2029)
5 Segment by Application
5.1 Global Optic Neuropathy Treatment Sales by Application (2018-2029)
5.1.1 Global Optic Neuropathy Treatment Sales by Application (2018-2023)
5.1.2 Global Optic Neuropathy Treatment Sales by Application (2024-2029)
5.1.3 Global Optic Neuropathy Treatment Sales Market Share by Application (2018-2029)
5.2 Global Optic Neuropathy Treatment Revenue by Application (2018-2029)
5.2.1 Global Optic Neuropathy Treatment Revenue by Application (2018-2023)
5.2.2 Global Optic Neuropathy Treatment Revenue by Application (2024-2029)
5.2.3 Global Optic Neuropathy Treatment Revenue Market Share by Application (2018-2029)
5.3 Global Optic Neuropathy Treatment Price by Application (2018-2029)
6 Key Companies Profiled
6.1 AbbVie Inc.
6.1.1 AbbVie Inc. Corporation Information
6.1.2 AbbVie Inc. Description and Business Overview
6.1.3 AbbVie Inc. Optic Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.1.4 AbbVie Inc. Optic Neuropathy Treatment Product Portfolio
6.1.5 AbbVie Inc. Recent Developments/Updates
6.2 Eli Lilly and Company
6.2.1 Eli Lilly and Company Corporation Information
6.2.2 Eli Lilly and Company Description and Business Overview
6.2.3 Eli Lilly and Company Optic Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Eli Lilly and Company Optic Neuropathy Treatment Product Portfolio
6.2.5 Eli Lilly and Company Recent Developments/Updates
6.3 GSK Plc.
6.3.1 GSK Plc. Corporation Information
6.3.2 GSK Plc. Description and Business Overview
6.3.3 GSK Plc. Optic Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.3.4 GSK Plc. Optic Neuropathy Treatment Product Portfolio
6.3.5 GSK Plc. Recent Developments/Updates
6.4 Pfizer Inc.
6.4.1 Pfizer Inc. Corporation Information
6.4.2 Pfizer Inc. Description and Business Overview
6.4.3 Pfizer Inc. Optic Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Inc. Optic Neuropathy Treatment Product Portfolio
6.4.5 Pfizer Inc. Recent Developments/Updates
6.5 Teva Pharmaceutical Industries Ltd.
6.5.1 Teva Pharmaceutical Industries Ltd. Corporation Information
6.5.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
6.5.3 Teva Pharmaceutical Industries Ltd. Optic Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Teva Pharmaceutical Industries Ltd. Optic Neuropathy Treatment Product Portfolio
6.5.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.6 Bausch Health Companies Inc.
6.6.1 Bausch Health Companies Inc. Corporation Information
6.6.2 Bausch Health Companies Inc. Description and Business Overview
6.6.3 Bausch Health Companies Inc. Optic Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bausch Health Companies Inc. Optic Neuropathy Treatment Product Portfolio
6.6.5 Bausch Health Companies Inc. Recent Developments/Updates
6.7 F. Hoffmann-La Roche AG
6.6.1 F. Hoffmann-La Roche AG Corporation Information
6.6.2 F. Hoffmann-La Roche AG Description and Business Overview
6.6.3 F. Hoffmann-La Roche AG Optic Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.4.4 F. Hoffmann-La Roche AG Optic Neuropathy Treatment Product Portfolio
6.7.5 F. Hoffmann-La Roche AG Recent Developments/Updates
6.8 Bayer AG
6.8.1 Bayer AG Corporation Information
6.8.2 Bayer AG Description and Business Overview
6.8.3 Bayer AG Optic Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bayer AG Optic Neuropathy Treatment Product Portfolio
6.8.5 Bayer AG Recent Developments/Updates
6.9 Sanofi S.A
6.9.1 Sanofi S.A Corporation Information
6.9.2 Sanofi S.A Description and Business Overview
6.9.3 Sanofi S.A Optic Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Sanofi S.A Optic Neuropathy Treatment Product Portfolio
6.9.5 Sanofi S.A Recent Developments/Updates
6.10 Bristol-Myers Squibb Company
6.10.1 Bristol-Myers Squibb Company Corporation Information
6.10.2 Bristol-Myers Squibb Company Description and Business Overview
6.10.3 Bristol-Myers Squibb Company Optic Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Bristol-Myers Squibb Company Optic Neuropathy Treatment Product Portfolio
6.10.5 Bristol-Myers Squibb Company Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Optic Neuropathy Treatment Industry Chain Analysis
7.2 Optic Neuropathy Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Optic Neuropathy Treatment Production Mode & Process
7.4 Optic Neuropathy Treatment Sales and Marketing
7.4.1 Optic Neuropathy Treatment Sales Channels
7.4.2 Optic Neuropathy Treatment Distributors
7.5 Optic Neuropathy Treatment Customers
8 Optic Neuropathy Treatment Market Dynamics
8.1 Optic Neuropathy Treatment Industry Trends
8.2 Optic Neuropathy Treatment Market Drivers
8.3 Optic Neuropathy Treatment Market Challenges
8.4 Optic Neuropathy Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

AbbVie Inc.
Eli Lilly and Company
GSK Plc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Bausch Health Companies Inc.
F. Hoffmann-La Roche AG
Bayer AG
Sanofi S.A
Bristol-Myers Squibb Company

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂